What are the criteria for staging acute kidney injury (AKI) and how should each stage be managed?

Staging Acute Kidney Injury (AKI)

AKI is staged using serum creatinine (sCr) changes and/or urine output criteria, with three progressive stages that directly correlate with mortality risk and guide management intensity.

Diagnostic Criteria for AKI

AKI is diagnosed when any of the following occur 1, 2:

• sCr increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, OR
• sCr increase ≥1.5 times (≥50%) from baseline within 7 days, OR
• Urine output <0.5 mL/kg/hour for 6 hours

Establishing Baseline Creatinine

The baseline sCr determination is critical and should follow this hierarchy 3, 4:

1. Most recent sCr within 3 months (use value closest to admission)
2. If unavailable, admission sCr becomes the baseline
3. Never use calculated/imputed baseline sCr in cirrhotic patients (formulas overestimate GFR and underdiagnose AKI) 5

AKI Staging System

Stage 1:

• sCr increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48h, OR
• sCr 1.5-1.9 times baseline, OR
• Urine output <0.5 mL/kg/h for 6-12 hours

Stage 2:

• sCr 2.0-2.9 times baseline, OR
• Urine output <0.5 mL/kg/h for ≥12 hours

Stage 3:

• sCr ≥3.0 times baseline, OR
• sCr ≥4.0 mg/dL (353.6 μmol/L) with acute increase ≥0.3 mg/dL, OR
• Initiation of renal replacement therapy, OR
• Urine output <0.3 mL/kg/h for ≥24 hours or anuria for ≥12 hours

3, 1, 2, 4

Special Consideration: Stage 1A vs 1B in Cirrhosis

In cirrhotic patients, Stage 1 should be subdivided based on prognostic differences 3:

• Stage 1A: sCr <1.5 mg/dL (worse outcomes)
• Stage 1B: sCr ≥1.5 mg/dL

Stage-Specific Management

Stage 1 Management

Immediate actions 5, 4:

1. Remove nephrotoxic insults:

   • Withdraw NSAIDs, vasodilators, nephrotoxic drugs
   • Taper or discontinue diuretics and β-blockers

2. Volume assessment and correction:

   • Expand plasma volume if hypovolemia suspected (crystalloids, albumin, or blood if GI bleeding)
   • Treat infections promptly when diagnosed or strongly suspected

3. Close monitoring:

   • Check sCr every 2-4 days during hospitalization
   • Outpatient sCr monitoring every 2-4 weeks for first 6 months post-discharge

Stage 2 and 3 Management

Escalated interventions 3, 5:

1. Mandatory diuretic withdrawal (if not already done)

2. Albumin volume expansion:

   • 1 g/kg body weight daily for 2 consecutive days
   • Maximum 100 g/day 4
   • Monitor for pulmonary edema (risk increased with cirrhotic cardiomyopathy/diastolic dysfunction)

3. Assess response after 48 hours:

   • Full response: sCr returns to within 0.3 mg/dL of baseline → close follow-up
   • Partial response: AKI stage regression but sCr remains ≥0.3 mg/dL above baseline → case-by-case management
   • No response/Progression: Evaluate for specific AKI phenotypes

4. For cirrhotic patients meeting HRS-AKI criteria 4:

   • Vasoconstrictors (terlipressin) plus albumin (20-40 g/day)
   • HRS-AKI diagnosis requires: cirrhosis with ascites, Stage ≥2 AKI, no response to volume expansion, absence of shock/nephrotoxic drugs/structural kidney disease

5. Nephrology consultation:

   • Emergent: Stage 2-3 AKI, Stage 1 with decompensated comorbidity, unclear etiology
   • Urgent: No improvement with treatment, suspected glomerulonephritis

Critical Pitfalls to Avoid

Urine output criteria limitations in cirrhosis: Cirrhotic patients with ascites are frequently oliguric despite normal GFR due to avid sodium retention and diuretic effects. Urine output criteria should only be applied when bladder catheterization is clinically indicated 3.

Creatinine measurement variability: sCr can be affected by decreased muscle mass, increased tubular secretion, volume overload, and bilirubin interference with assays—all common in cirrhosis 5, 6. Serial measurements are more reliable than single values.

Albumin administration risks: In recent trials, 8% of terlipressin-treated patients (especially ACLF-3) developed respiratory failure, with trends toward higher risk in those receiving larger albumin volumes pre-treatment 4. Carefully monitor for volume overload.

Progression monitoring: Approximately 25-30% of AKI episodes are community-acquired and present on admission 3. Document whether AKI is present at admission versus hospital-acquired, as this affects prognosis and management urgency.